•  
  •  
 

Abstract

Objectives: to evaluate the role of Neuropilin-1 as a prognostic biomarker of lupus nephritis. Background: Lupus nephritis, one of the most serious manifestations of systemic lupus erythematosus (SLE). NPL-1 could serve, as a biomarker to distinguish both types of glomerulonephritis and its measurement is not only useful in diagnosis but also a reliable marker of renal disease activity in patients with SLE. Methods: 60 patients diagnosed with SLE and sixty age and sex matched healthy volunteers were included in this study. Selection of patients of the present study based on the Systemic Lupus International Collaborating Clinics (SLICC) criteria for classification of SLE with disease duration at least six months. SLE disease activity was assessed by using Systemic lupus Erythematosus Disease Activity Index (SLEDAI). All patients and controls were subjected to measurement of human Neuropilin-1 level in serum and urine by ELISA (Cat number: E2101Hu Human). Results: In this study Neuropilin-1 in urine and serum was insignificantly different between mild and moderate group while was significantly lower in mild group and moderate group than severe group (P value2. Also, neuropilin-1 in serum can significantly predict lupus nephritis (P

Subject Area

Rheumatology

Article Type

Original Study

Creative Commons License

Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License
This work is licensed under a Creative Commons Attribution-NonCommercial-Share Alike 4.0 International License.

Share

COinS